AKT1 and melanoma: Furthermore, a short-term BRAFi treatment (48–72 h) induced the fibronectin expression and deposition by melanoma cells; this, in turn, protected tumour cells through α5β1-integrin-PI3K-AKT-MCL1-mediated survival [115].